

## Cystic Fibrosis, *CFTR* Gene, Variant Panel, Varies

**Test ID:** CFMP

### Useful for:

- Confirmation of a clinical diagnosis of cystic fibrosis
- Reproductive risk refinement via carrier screening for individuals in the general population
- Reproductive risk refinement via carrier screening for individuals with a family history when familial variants are not available
- Identification of patients who may respond to cystic fibrosis transmembrane conductance regulator (*CFTR*) potentiator therapy

### Genetics Information:

This test includes targeted testing to evaluate over 500 genetic variants including 23 pathogenic variants recommended by the American College of Medical Genetics and Genomics.

For details regarding the specific variants identified by this test see [Targeted Variants Interrogated by Cystic Fibrosis Variant Panel](#).

### Methods:

Targeted Genotyping Array

### Reference Values:

An interpretive report will be provided

### Ordering Guidance:

- If testing is negative, and a diagnosis of cystic fibrosis is still suspected, consider CFTRZ / *CFTR* Gene, Full Gene Analysis, Varies.
- Targeted testing for familial variants (also called site-specific or known mutation testing) is available for all genes on this panel under FMTT / Familial Mutation, Targeted Testing, Varies. Call 800-533-1710 to obtain more information about this testing option.

### Necessary Information:

If there is a family history of cystic fibrosis, the known variant in the family should be supplied for best interpretation of results.

## Specimen Requirements:

<b>Specimen Type:</b>	Whole blood
<b>Patient Preparation:</b>	A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
<b>Preferred:</b>	Lavender top (EDTA) or yellow top (ACD)
<b>Acceptable:</b>	Any anticoagulant
<b>Specimen Volume:</b>	3 mL
<b>Collection Instructions:</b>	1. Invert several times to mix blood. 2. Send whole blood specimen in original tube. <b>Do not</b> aliquot.
<b>Additional Information:</b>	To ensure minimum volume and concentration of DNA is met, the preferred volume of blood must be submitted. Testing may be canceled if DNA requirements are inadequate.
<b>Minimum Volume:</b>	1 mL

## Note:

Specimen preferred to arrive within 96 hours of collection.

## Specimen Stability Information:

Specimen Type	Temperature	Time	Special Container
Varies	Ambient (preferred)		
	Frozen		
	Refrigerated		

## Cautions:

- This assay will not detect all known disease-associated variants that cause cystic fibrosis (CF) or CFTR-related disorders. Therefore, the absence of a detectable variant does not rule out the possibility that an individual is a carrier of or affected with this disease.
- A negative result does not eliminate the risk of carrier status for any of the included conditions, due to the possibility that the patient carries a variant that is not interrogated with this assay or the rare chance of a false-negative result for a tested variant. For tested variants, the negative predictive value of this screen is greater than 98%. The patient's residual risk to be a carrier after a negative screen is dependent on ethnic background and family history.
- A positive control was not available for all variants targeted on this panel. For more information regarding availability of a positive control for each variant see [Targeted Variants Interrogated by Cystic Fibrosis Variant Panel](#). The negative predictive value of these targets is unknown.
- Rare variants (ie, polymorphisms) exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.
- All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.<sup>(1)</sup> This assay was designed to specifically target known pathogenic or likely pathogenic variants. In rare cases, DNA variants of undetermined significance may be identified. The laboratory encourages healthcare providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time.

- Multiple in-silico evaluation tools may have been used to assist in the interpretation of these results. Of note, the sensitivity and specificity of these tools for the determination of pathogenicity is currently unvalidated.
- Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.
- Bone Marrow transplants from allogenic donors will interfere with testing. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.
- An online research opportunity called GenomeConnect ([genomeconnect.org](http://genomeconnect.org)), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects deidentified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

**CPT Code:**

81220

81222

**Day(s) Performed:** Thursday & Sunday**Report Available:** 14 to 42 days**Questions**

Contact Michelle Rath, Laboratory Technologist Resource Coordinator at 800-533-1710.